{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal ALLO-ASC",
            "NStudiesAvail": 430108,
            "NStudiesFound": 22,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 22,
            "FieldList": [
                  "MaximumAge",
                  "MinimumAge",
                  "NCTId",
                  "NCTIdAlias",
                  "OfficialTitle",
                  "OrgClass",
                  "OrgFullName",
                  "OrgStudyId",
                  "OrgStudyIdDomain",
                  "OrgStudyIdLink",
                  "OrgStudyIdType",
                  "OtherEventAssessmentType",
                  "OtherEventNotes",
                  "OtherEventOrganSystem",
                  "OtherEventSourceVocabulary"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "MaximumAge": [
                              "90 Years"
                        ],
                        "MinimumAge": [
                              "19 Years"
                        ],
                        "NCTId": [
                              "NCT01856140"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells(ALLO-ASC):A Pilot Study"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Seoul National University Hospital"
                        ],
                        "OrgStudyId": [
                              "SNUH-RM-SGChung-ASC-01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [
                              "Systematic Assessment"
                        ],
                        "OtherEventNotes": [
                              "Although mild swelling was seen at the injection site in six participants (three in group 1 and three in group 2) within 48 hours after injection, the regional swelling subsided spontaneously (without any treatment) within 2 weeks."
                        ],
                        "OtherEventOrganSystem": [
                              "Musculoskeletal and connective tissue disorders"
                        ],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 2,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "19 Years"
                        ],
                        "NCTId": [
                              "NCT03449082"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Treatment of Intractable Common Extensor Tendon Injury Using Allogeneic Adipose-derived Mesenchymal Stem Cells (Allo-ASC): a Phase II Randomized Controlled Trial"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Seoul National University Hospital"
                        ],
                        "OrgStudyId": [
                              "SNUH-RM-SGChung-ASC-02"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 3,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "19 Years"
                        ],
                        "NCTId": [
                              "NCT02384499"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Treatment of Fecal Incontinence Using Allogenic-Adipose-derived Mesenchymal Stem Cells: A Prospective, Dose Escalation, Randomized, Placebo-controlled, Parallel-group, Single-blind, Single-center Pilot Study"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Yonsei University"
                        ],
                        "OrgStudyId": [
                              "3-2014-0271"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 4,
                        "MaximumAge": [
                              "80 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04497805"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase 2 Clinical Study to Evaluate The Efficacy and Safety of ALLO-ASC-SHEET in the Subjects With Diabetic Wagner Grade II Foot Ulcers"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Anterogen Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "ALLO-ASC-SHEET"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 5,
                        "MaximumAge": [
                              "80 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT02619877"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Phase 2 Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers: A Randomized, Comparator-controlled, Single-blind, Parallel-group, Multi-center Study"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Anterogen Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "ALLO-ASC-DFU-201"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 6,
                        "MaximumAge": [
                              "80 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03754465"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of ALLO-ASC-SHEET in Subjects With Diabetic Foot Ulcers"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Anterogen Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "ALLO-ASC-SHEET-102"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 7,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT02619851"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase II Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury Subjects: Controlled, Parallel, Multicenter"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Anterogen Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "ALLO-ASC-BI-201"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 8,
                        "MaximumAge": [
                              "75 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03370874"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Phase 3 Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center Study"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Anterogen Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "ALLO-ASC-DFU-301"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 9,
                        "MaximumAge": [
                              "80 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03183726"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Follow-up Study to Evaluate the Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1 Clinical Trial of ALLO-ASC-DFU-101"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Anterogen Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "ALLO-ASC-DFU-102"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 10,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03183661"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in the Subjects With Crohn\u00b4s Disease(ALLO-ASC-CD-101)"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Anterogen Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "ALLO-ASC-CD-102"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 11,
                        "MaximumAge": [
                              "90 Years"
                        ],
                        "MinimumAge": [
                              "19 Years"
                        ],
                        "NCTId": [
                              "NCT02298023"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells: Phase II Double-Blind Placebo-Controlled Randomized Clinical Trials."
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Seoul National University Hospital"
                        ],
                        "OrgStudyId": [
                              "ALLO-ASC_TR"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment"
                        ],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [
                              "Psychiatric disorders",
                              "Eye disorders",
                              "Musculoskeletal and connective tissue disorders",
                              "Musculoskeletal and connective tissue disorders",
                              "Musculoskeletal and connective tissue disorders"
                        ],
                        "OtherEventSourceVocabulary": [
                              "CTCAE (4.0)",
                              "CTCAE (4.0)",
                              "CTCAE (4.0)",
                              "CTCAE (4.0)",
                              "CTCAE (4.0)"
                        ]
                  },
                  {
                        "Rank": 12,
                        "MaximumAge": [
                              "80 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03183804"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Follow-up Study to Evaluate the Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 2 Clinical Trial of ALLO-ASC-DFU-201"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Anterogen Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "ALLO-ASC-DFU-202"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 13,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03113747"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Safety and Efficacy Evaluation of Tissue Engineered Construct Based on Allogeneic Adipose-derived Multipotent Mesenchymal Stromal Cells and Platelet-poor Plasma Fibrin Hydrogel to Treat the Patients With Burn Wounds"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "A.A. Partners, LLC"
                        ],
                        "OrgStudyId": [
                              "MSC-P1"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 14,
                        "MaximumAge": [
                              "60 Years"
                        ],
                        "MinimumAge": [
                              "10 Years"
                        ],
                        "NCTId": [
                              "NCT02579369"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase 1/2 Clinical Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Anterogen Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "ALLO-ASC-EB-101"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 15,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT02580617"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase 1 Clinical Study to Evaluate the Safety of Allogeneic Adipose-derived Stem Cells in the Subjects With Crohn's Disease"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Anterogen Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "ALLO-ASC-CD-101"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 16,
                        "MaximumAge": [
                              "80 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT02394886"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase I Clinical Study to Evaluate the Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Anterogen Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "ALLO-ASC-DFU-101"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 17,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT02394873"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase 1 Clinical Study to Evaluate the Safety of Allogeneic Adipose-derived Stem Cells in the Subjects With Deep Second-degree Burn Wound"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Anterogen Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "ALLO-ASC-BI-101"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 18,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03183622"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Follow-up Study to Evaluate the Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1 Clinical Trial of ALLO-ASC-BI-101"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Anterogen Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "ALLO-ASC-BI-102"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 19,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03183648"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Follow-up Study to Evaluate the Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 2 Clinical Trial of ALLO-ASC-BI-201"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Anterogen Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "ALLO-ASC-BI-202"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 20,
                        "MaximumAge": [
                              "75 Years"
                        ],
                        "MinimumAge": [
                              "19 Years"
                        ],
                        "NCTId": [
                              "NCT04569409"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Phase 3 Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers: A Randomized, Comparator-controlled, Double-blind, Parallel-group, Multi-center Study"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Anterogen Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "ALLO-ASC-DFU-302"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 21,
                        "MaximumAge": [
                              "60 Years"
                        ],
                        "MinimumAge": [
                              "2 Years"
                        ],
                        "NCTId": [
                              "NCT03183934"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Follow-up Study to Evaluate the Efficacy and Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1/2 Clinical Trial of ALLO-ASC-EB-101"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Anterogen Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "ALLO-ASC-EB-102"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 22,
                        "MaximumAge": [
                              "60 Years"
                        ],
                        "MinimumAge": [
                              "4 Years"
                        ],
                        "NCTId": [
                              "NCT05157958"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Double Blind, Randomized, Phase II Clinical Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET Versus Vehicle Control in Dystrophic Epidermolysis Bullosa (DEB) Patients"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Anterogen Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "ALLO-ASC-DEB-201"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  }
            ]
      }
}